Accessibility Menu
Palisade Bio logo

Palisade Bio(NASDAQ) PALI

Market Cap$355.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year+155%
1 Month+4%
$2.13
+4.17%
+0.09Today
Palisade Bio last closing stock price
MetricPriceDate
Last closeUSD 2.042026-08-18
Palisade Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.67%USD 2.142026-08-11
1 month+3.55%USD 1.972026-07-17
3 month+8.51%USD 1.882026-05-20
Year to date-13.19%USD 2.352025-12-31
1 year+154.68%USD 0.802025-08-18
3 year-77.7%USD 9.152023-08-18
5 year-99.89%USD 1,852.502021-08-19
Since inception-99.97%USD 7,687.502021-04-28

Palisade Bio Financials at a Glance

Market Cap

$355.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$500.00K

Net Income (TTM)

-$31.94M

EPS (TTM)

-$0.54

P/E Ratio

-3.81

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$2.13

Volume

1,294,124.173

Open

$2.10

Previous Close

$2.04

Daily Range

$2.09 - $2.19

52-Week Range

$0.53 - $2.86

Estimated Earnings Date

Nov 9, 2026

PALI News

No articles available.

PALI: Motley Fool Moneyball Superscore

36

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Palisade Bio

Palisade makes pills for people with serious gut diseases. These medicines help fix the protective lining of the digestive tract. They aim to reduce pain and swelling for patients.

Smarter Medicines for the Gut

  • PALI-2108: Oral drug designed to treat swelling in the colon and lower intestine for patients with inflammatory bowel disease.
  • Precision Medicine: Testing system using patient data to help doctors find who will benefit most from treatment.
  • LB1148: Liquid used to keep the gut healthy during surgery or infections.

Strategic Moves and Expansion

  • Licensed rights from Giiant Pharma Inc. in September 2023 to develop its lead drug candidate.
  • Started human trials in November 2024 after receiving approval from Health Canada.
  • Began studying patients with severe bowel scarring in October 2025.
  • Worked with Newsoara to develop and sell gut treatments in the Chinese market.

Targeted Treatment in Action

The company creates drugs that remain inactive until they reach specific bacteria in the lower gut. This delivery method helps the medicine work where needed while reducing risk to the rest of the body.

Key Data and Figures

  • Operating income was -$10 million in Q4 2025, worsening 195.1% from Q4 2024.
  • Net income reached -$8.9 million in Q4 2025, a 166.1% decline from the prior year.
  • Free cash flow dropped to -$3.1 million in Q4 2025, down 32% year-over-year.
  • Market value hit $130.8 million in Q4 2025, up 1,262.8% from $9.6 million in Q4 2024.

Bottom Line

Palisade has moved from early research to clinical testing of its targeted gut treatments. The company relies on its licensed technology and strategic partnerships to develop its drug pipeline.

AI Generated • May 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

J. D. Finley

Website

www.palisadebio.com

Headquarters

Denver, CA 80237, US

PALI Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-7069.80%

Net Income Margin

-6388.20%

Return on Equity

-33.47%

Return on Capital

-13.95%

Return on Assets

-25.09%

Earnings Yield

-26.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$355.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

174.27M

Volume

1.29M

Avg. Volume

3.14M

Financials (TTM)

Gross Profit

$500.00K

Operating Income

-$35.35M

EBITDA

-$33.22M

Operating Cash Flow

-$18.19M

Capital Expenditure

$0.00

Free Cash Flow

-$18.19M

Cash & ST Invst.

$125.17M

Total Debt

$0.00

Palisade Bio Performance Analysis

Palisade Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 250,000N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Palisade Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Palisade Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -247.89-90.3%
20232023-12-31USD -27.01-89.1%
20242024-12-31USD -10.19-62.3%
20252025-12-31USD -0.30-97.0%
Palisade Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3034.5%
Q42025-12-3185.3%
Q12026-03-3117.9%
Q22026-06-30-9.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$500.00K

N/A

Gross Profit

$500.00K

N/A

Gross Margin

100.00%

N/A

Market Cap

$355.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$25.39M

N/A

Employees

14

N/A

Net Income

-$10.57M

-279.8%

EBITDA

-$10.57M

-280.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$125.17M

+2210.7%

Total Debt

$0.00

-100.0%

Accounts Receivable

$500.00K

+8233.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-25.09%

N/A

Return on Invested Capital

-28.96%

N/A

Free Cash Flow

-$7.60M

-318.4%

Operating Cash Flow

-$7.60M

-318.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCTXBriaCell Therapeutics Corp.
$3.83+8.50%
LPTXLeap Therapeutics, Inc.
$0.77-3.15%
ATHAAthira Pharma, Inc.
$6.75-6.12%
ENTOEntero Therapeutics, Inc.
$2.85-5.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MRNAModerna
$148.22+1.35%
BITOProShares Trust - ProShares Bitcoin ETF
$9.28+0.06%
IBITiShares Bitcoin Trust
$38.90+0.06%
INTCIntel
$93.72-0.03%

Questions About PALI

What is the current price of Palisade Bio?

Palisade Bio is trading at $2.13 per share.

What is the 52-week range for Palisade Bio?

Over the past 52 weeks, Palisade Bio has traded between $0.53 and $2.86.

How much debt does Palisade Bio have?

As of the most recent reporting period, Palisade Bio reported total debt of $0.00.

How much cash does Palisade Bio have on hand?

Palisade Bio reported $125.17M in cash and cash equivalents in its most recent financial results.

What is Palisade Bio’s dividend yield?

Palisade Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services